Alice Goodman
Targeted PET imaging shows promise in prostate Ca
Targeted PET imaging shows promise in prostate Ca
A novel compound used with positron emission tomography imaging can identify foci of prostate cancer not found on biopsy of the prostate pre surgery or on the post-surgery specimen, according to a pilot study presented at the American Association of Cancer Research annual meeting in Philadelphia.
Male pattern baldness linked to prostate Ca mortality
Male pattern baldness linked to prostate Ca mortality
A large prospective study suggests men with male pattern baldness (MPB), particularly moderate MPB, are more likely to die from prostate cancer, compared to men with no MPB.
Adjuvant therapy fails in locally advanced kidney Ca
Two angiogenesis inhibitors that are widely used in metastatic renal cell carcinoma did not improve survival compared with placebo when used as adjuvant treatment, a new study found.
Study: Low-dose-rate BT outperforms EBRT boost
Study: Low-dose-rate BT outperforms EBRT boost
An iodine-125 low-dose-rate brachytherapy boost outperformed dose-escalated external beam radiotherapy boost in achieving biochemical progression-free survival in men with unfavorable risk prostate cancer, according to results of a recent multicenter trial.
Growth factor inhibition shows promise in bladder Ca
Preliminary studies suggest that inhibition of fibroblast growth factor receptors (FGFR) 1, 2, 3, and 4 may be a promising approach for the treatment of bladder cancers and other cancers that harbor FGFR alterations.
Protein may predict resistance to prostate cancer Tx
Researchers have come up with a potential blood-based biomarker that can identify men with castration-resistant prostate cancer who are not likely to respond to enzalutamide (XTANDI).
Bladder cancer study identifies therapeutic targets
A comprehensive molecular characterization of muscle-invasive urothelial bladder carcinoma suggests multiple opportunities for therapeutic intervention.
Sequential therapies for metastatic renal cell carcinoma yield similar results
The sequential use of two targeted treatments for metastatic renal cell carcinoma appears to yield similar total progression-free survival regardless of the order in which they are given, phase III study results indicate.
Semi-annual PSA may be safe for men on surveillance
Some men with low-risk prostate cancer who are being managed by active surveillance can have their PSA levels measured every 6 months instead of every 3 months, researchers reported at the American Society of Clinical Oncology annual meeting in Chicago.
5-ARI does not affect prostate cancer mortality
Eighteen years of follow-up of the Prostate Cancer Prevention Trial (PCPT) suggests that 7 years of treatment with the 5-alpha-reductase inhibitor finasteride (Proscar) for prostate cancer prevention does not appear to affect mortality but does reduce the risk of a prostate cancer diagnosis.